Sulfonamides

Sulfonamides

http://evolve.elsevier.com/Edmunds/NP/

Class	Subclass	Generic Name	Trade Name
Sulfonamides	Short to medium acting	sulfisoxazole	Generic, Gantrisin
		sulfamethoxazole	Gantanol, generic
		sulfadiazine	Generic
		trimethoprim and sulfamethoxazole ([TMP/SMX])	Bactrim DS, Septra DS
	Active in gut	sulfasalazine	Azulfidine, see Chapter 31
	Topical	sulfacetamide	See Chapter 14
		silver sulfadiazine	Silvadene

INDICATIONS

See Table 65-1 for specifics.

TABLE 65-1

Sulfonamide Indications with Dosage and Administration Recommendations

Drug	Bacteria	Site/Disease	Dosage
sulfisoxazole	H. influenzae, S. pneumoniae, Pneumocystis jiroveci, Pneumocystis pneumoniae, toxoplasmosis, isosporosis, typhoid fever, pertussis, nocardiosis, and listeriosis	UTI, otitis media, bronchitis, pneumonia, traveler’s diarrhea, diverticulitis, sinusitis, dog bite	Adult: Loading dose 2-4 g, maintenance 4-8 g/day in 4-6 divided doses Child (>2 mo): Initial dose 75 mg/kg, then 120-150 mg/kg/day (maximum, 6 g/day) in 4-6 divided doses
sulfamethoxazole	Same	Same	Adult: 2 g initially, maintenance dose 1 g bid Child (>2 mo): Initially 50-60 mg/kg, maintenance dosage 25-30 mg/kg bid
sulfadiazine	Same	Same	Adult: Loading dose 2-4 g, then 2-4 g/day in 3-6 divided doses Child (>2 mo): Loading 75 mg/kg, maintenance 150 mg/kg/day in 4-6 divided doses; see detailed reference for further dosing information for infants and newborns
TMP/SMX	Same plus Shigella flexneri	UTI and otitis media, shigellosis (× 5 days)	Adult: 160 TMP/800 SMX q12h × 10-14 days; see detailed reference for further dosing information on other infections Child (>2 mo): Dose based on TMP component. Doses vary according to severity and location of infection. Usual range: 6-12 mg/kg/day TMP in 2 divided doses × 10 days

• Acute exacerbation of COPD

• Traveler’s diarrhea

• Diverticulitis

The sulfonamides have a wide antibacterial spectrum that includes both gram-positive and gram-negative organisms; they are most commonly used for UTIs. Sulfonamide therapy continues to have a place in the treatment or prophylaxis of specific clinical conditions such as Pneumocystis pneumonia, toxoplasmosis, isosporosis, typhoid fever, pertussis, nocardiosis, and listeriosis. Strains of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) have emerged as an important group of pathogens. Sulfonamides and tetracycline antibiotics remain valuable low-cost agents for use with most CA-MRSA soft tissue and skin infections.

Frequent allergic reactions and drug resistance limit the more extensive use of sulfonamides. Sulfamethoxazole is combined with trimethoprim (TMP/SMX) for its synergistic effect and is the most commonly used of the sulfonamides. Silver sulfadiazine is frequently used in wound infections and burns. Sulfonamides are divided into four classes. Two are systemic antibiotics (short acting and long acting); for topical infections and bowel problems. Short-acting agents are rapidly absorbed and rapidly eliminated. Long-acting agents are rapidly absorbed but are excreted slowly. No long-acting sulfonamides are currently available in the United States because of associated toxicity, especially seen as Stevens-Johnson syndrome. Poorly absorbed sulfonamides are used to treat infections of the bowel and to prepare individuals for surgery. Topicals include sulfonamides that are not absorbed systemically; these are used topically, particularly in the eye and ear. The first antibiotic was a sulfonamide that was developed by the German dye industry; it was first used in 1932 against streptococcal infection.

Therapeutic Overview

Allergy

Sulfonamide or “sulfa” allergy is fairly common, occurring in about 6% of the general population. Allergic reactions to sulfonamides are divided into type 1 (immediate hypersensitivity) and types 2 to 4 (IgG and IgM antibody, and T-cell mediated). Allergies occur to sulfonamide metabolites at the N1 and N4 amino nitrogen on the heterocyclic ring. Only the antibiotic sulfonamide drugs have this structure. Nonantibiotic sulfonamide drugs do not contain this structure. Although much concern has been expressed about cross-allergy with other drugs that contain a sulfonamide functional group, research has shown that this does not occur. A theoretical possibility remains that a T-cell–mediated allergy could possibly be related to the sulfonamide compound. This has not yet been demonstrated. The fact that people who have an allergy to a drug often have many allergies confuses the picture. For example, some patients have an allergy to penicillin and an allergy to cephalosporins that are not related. The data suggest that patients who are allergic to sulfonamide antibiotics do not need to avoid nonantibiotic sulfonamides.

Type 1 immediate sensitivity reactions include anaphylaxis, urticaria, angioedema, and hypotension that occur within 30 minutes of drug administration. Type 2 hypersensitivity (cytotoxic) reactions cause hemolytic anemias, neutropenias, thrombocytopenias, and vasculitides, which generally become apparent within 7 to 14 days of administration. Type 3 hypersensitivity reactions affect entire organs. Skin, joints, and kidneys often are affected. Classic serum sickness syndrome (i.e., fever, vasculitis, lymphadenopathy, rashes, and urticaria) is also included in this category. These symptoms occur days to weeks after initiation of administration. Type 4 (cell-mediated or delayed hypersensitivity) is mediated by cytokines released by T-cells. Maculopapular rashes, Stevens-Johnson syndrome, and toxic epidermal necrolysis are examples. These conditions usually take 48 to 72 hours to develop.

Resistance

Resistance is a common problem that limits the usefulness of sulfonamides. Streptococci, staphylococci, Enterobacteriaceae, Neisseria, and Pseudomonas are resistant. The single mechanism of resistance is random mutation, which results in overproduction of para-aminobenzoic acid (PABA) or structural changes in an enzyme. Transfer of resistance occurs through plasmids. Plasmid-mediated resistance has become more common, especially with trimethoprim. Resistance also is decreased by bacterial permeability.

< div class='tao-gold-member'>

Only gold members can continue reading. Log In or Register to continue

Related

Stay updated, free articles. Join our Telegram channel

Tags: Pharmacology for the Primary Care Provider

Jul 22, 2016 | Posted by admin in PHARMACY | Comments Off

Full access? Get Clinical Tree

Get Clinical Tree app for offline access

Get Clinical Tree app for offline access